Evaluation of the safety and efficacy of renal denervation with a standard irrigated cardiac ablation catheter (SICAC) in chronic kidney disease (CKD) patients with refractory hypertension.
Introduction
Hypertension is considered one of the major modifiable risk factors for the development of cardiovascular disease and one of the most important public health problems in the world. 1 It is also recognized as one of the most important risk factors for the development and progression of chronic kidney disease (CKD). 2 Chronic kidney disease patients often are refractory to drug treatment, even with the association of several antihypertensive substances. 3 Recently, an approach employing percutaneous catheter-based delivery of radiofrequency (RF) energy was developed to interrupt the renal sympathetic innervation. This new technique showed no severe vascular or renal complications in the long term (up to 24 months). 4 -8 Studies on renal denervation (RDN) with patients without CKD and taking three or more antihypertensive drugs in maximal doses have reported a significant and sustained reduction in systolic and diastolic blood pressures. 4 -8 The use of a standard cardiac ablation catheter initially designed for cardiac has been proved safe and feasible. 7,9 -12 Its use could extend the application of the RDN to patients from countries in which catheters specifically designed for the procedure are not available, at a lower cost. Chronic kidney disease patients have a high frequency of hypertension and are often refractory to drug treatment, even with the association of several antihypertensive substances. 3 The pathophysiology of hypertension in CKD presents some peculiarities such as the reduced ability of these patients to excrete salt and water. In particular, renal sympathetic nerves, afferent and efferent, which lie within and immediately adjacent to the wall of the renal artery, are crucial for the initiation and maintenance of hypertension. Several studies show that sympathetic overactivity is present in patients with renal disease 13 and in experimental models of CKD 14 since the beginning of the course of the disease. 15 This overactivity is thought to be mediated by signals arising from the failing kidneys. 16 It should also be stressed that uncontrolled hypertension has a significant adverse impact on progression of CKD. 17, 18 Taken together, these data make this group of patients particularly suitable to benefit from the procedure. This study aims to evaluate whether percutaneous RDN by RF energy delivered by a standard irrigated cardiac ablation catheter (SICAC) would be safe and effective in reducing blood pressure (BP) in patients with CKD 19 refractory to antihypertensive drug therapy and evaluate the impact of the procedure on estimated glomerular filtration rate (eGFR) and urinary albumin excretion.
Methods
In this study, we conducted a prospective, longitudinal study in 24 patients with refractory hypertension and CKD stages 2, 3, and 4 who underwent transcatheter renal artery denervation. The Committee of Ethics in Research of the Medical School of Universidade Federal Fluminense approved the study and an informed consent was signed by all patients. and (iii) age from 18 to 70 years. Exclusion criteria were pregnancy, valvular heart disease with significant haemodynamic consequences; use of warfarin, stenotic valvular heart disease for which the reduction in BP could be dangerous; acute myocardial infarction, unstable angina, stroke, or transitory ischaemic attack within the previous 6 months; renovascular anomalies (including renal artery stenosis, angioplasty with or without stenting, or double or multiple main arteries in the same kidney); and diabetes mellitus type 1 or other secondary cause for hypertension.
Study subjects
All patients involved in this study were already treated for hypertension for at least a year. Baseline medication was unchanged for at least 3 months before renal nerve ablation.
Study procedures and assessment
In this study, we treated 24 patients (9 men and 15 women) with CKD (stages 2, 3, and 4), and grade 2 and 3 systemic arterial hypertension. Patients underwent a complete medical history and physical examination. Hypertension was diagnosed on the basis of the current Brazilian Society of Cardiology guidelines and of the current European Society of Cardiology guidelines, for the management of arterial hypertension. 21, 22 Patients had previously been screened for secondary forms of hypertension according to current guidelines. 21, 22 All the patients underwent history and physical examination, and the antihypertensive medication was reviewed. The BP measurements were performed in the stand, sitting, and supine positions on at least two subsequent visits in both arms. Patients also were submitted to blood sampling for entire blood count and biochemistry (including serum creatinine to estimate GFR). Urine samples were obtained for determination of albuminuria, protein, and creatinine. Twenty-four hour ambulatory blood pressure monitoring (ABPM), echocardiogram, and Echo Doppler evaluation of the anatomy of the renal arteries of patients were also performed.
To evaluate the true effects of RDN on BP and additional measures, baseline medication was unchanged for at least 3 months before renal nerve ablation and treatment was maintained at follow-up. The patients were instructed not to change the medications and dosages after the procedure unless clinically indicated. Drug records and adherence of each patient were comprehensively reviewed and documented at each visit.
All the patients received i.v. sodium bicarbonate (3 mL/kg) and 0.9% saline for 1 h, as prophylaxis for attenuation of iodinated contrast media-associated nephrotoxicity. 23, 24 Under the supervision of an anaesthesiologist, patients were pretreated with diazepam or midazolam. Catheterization of the femoral artery by the standard Seldinger technique was performed after s.c. injection of local anaesthetic in the inguinal region. An 8-Fr valved sheath was introduced into this artery and unfractionated heparin was administered as i.v. bolus, targeting an activated coagulation time (ACT) .250 s in the first 10 min. During the procedure the ACT targeted range was 250 -350 s. Subsequently, using an 8-F Balkin introducer, an angiogram of the aorta and renal arteries were performed, and the 7-Fr irrigated ablation catheter was inserted (AlCath Flux eXtra Gold Full Circle 2708; VascoMed GmbH, Binzen, Germany) inside the renal artery, allowing the delivery of RF energy to the renal artery innervation. Because the application of RF is usually very painful, fentanyl was intravenously administered before the procedure. Radiofrequency applications were performed within the main stem of the renal arteries, bilaterally, with a series of applications with 8 W power, 60 s duration each, with an irrigation flow rate of 17 mL/min, aiming .4 RF applications per renal artery, according to their length. These points ablated were made with at least 5 mm distance between them and moving the catheter from the distal to the proximal in circumferential manner. The number of lesions per artery was chosen based on the artery length measurement by baseline angiography. For arteries shorter than 20 mm, a minimum of four lesions were applied, and for every increase in 5 mm length one additional lesion was provided. After the procedure, the anatomy of the renal arteries was checked by angiography to assess whether there were any complications during the procedure. At the end of procedure, patients were submitted to another infusion of sodium bicarbonate (1 mL/kg/h) for 6 h. 23, 24 After the procedure, patients remained hospitalized for a period of 24 h in a ward. The follow-up was performed weekly for the first month and monthly from the second to the sixth month. In every visit to the office, BP was measured after standing for 10 min in both upper limbs in sitting and supine positions, being considered for the study the mean of four measures. For every change in patient position (standing, sitting, and supine), there was a pause of 5 min. Samples were collected for blood and urine tests to monitoring the variables on the 30, 60, 90, and 180th days. Ambulatory blood pressure monitoring was performed on the first, third, and sixth month after the procedure to evaluate the BP and effectiveness of RDN. Echo Doppler was also performed to evaluate the anatomy of the renal arteries of patients, at first and sixth month after the RDN. The following variables were monitored during the follow-up period: systolic and diastolic BP, number and doses of antihypertensive medications, eGFR, and albuminuria.
Statistical analysis
The results were expressed as mean and standard deviation (mean + SD) of the mean in case of normal distribution and as the median with inter-quartile range otherwise. Statistical tests were all two-sided. 
Ablation procedure
In this patient cohort, 410 ablation spots were performed. The average of the number of lesions delivered was 9 + 3 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in the right renal artery, and 9 + 3 (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in the left renal artery. The mean duration of ablation was 1025 + 355 s of RF per patient (range 600-1680 s), the duration of the procedure ranged from 30 to 60 min, and the mean exposure time to fluoroscopy was 20 + 6 min.
Efficacy in blood pressure reduction
All the patients submitted to ablation of renal arteries showed highly significant reduction in office BP, both systolic and diastolic at all times points after the procedure. Accordingly, BP diminished from 186 + 19/108 + 13 to 133 + 11/85 + 7, 135 + 10/88 + 8, 137 + 11/90 + 7, 136 + 12/89 + 8, and 135 + 13 mmHg/88 + 7 mmHg at 7, 30, 60, 90, and 180th day, respectively (P , 0.0001 for systolic and diastolic values at every instance vs. baseline) ( Figure 1 ). Interestingly, a significant correlation was found between the decrease in office systolic blood pressure at the 180th day and the total number of ablation spots (r ¼ 0.4830, P ¼ 0.0168).
The reduction of the average values of systolic and diastolic blood pressure also was significant in 24 h ABPM, after the 30, 90, and 180th day of procedure, with a reduction from 151 + 18/92 + 11 to 133 + 13 mmHg/83 + 8 mmHg (P , 0.0001 for both comparisons), 132 + 13 mmHg/84 + 7 mmHg (P , 0.0001 for systolic and P ¼ 0.0001 for diastolic), and 132 + 15 mmHg/85 + 11 mmHg (P , 0.0001 for systolic and P ¼ 0.0015 for diastolic), respectively ( Figure 2) . The reduction took place in the mean arterial pressure at all daytime, 112 + 14 mmHg at baseline vs. 101 + 9 mmHg (P , 0.0001), 101 + 7 mmHg (P , 0.0001), and 101 + 11 mmHg (P , 0.0001), at the 30, 90, and 180th days, respectively, and during the sleep, 105 + 16 mmHg at baseline vs. 96 + 12 mmHg (P ¼ 0.0004), 95 + 11 mmHg (P , 0.0001), and 96 + 12 mmHg (P ¼ 0.0002), at the 30, 90, and 180th days, respectively. The number of non-dippers before and at 180 days after the procedure remained unchanged (16/24) . Similarly, the magnitude of decrease in the mean arterial pressure during the sleep, when comparing baseline (6.7 + 12.8 mmHg) with the 180th day postprocedure (6.2 + 8.0 mmHg) did not differ (P ¼ 0.9939). The distribution of systolic blood pressure into categories of severity also improved when compared before and after the procedure (Figure 3) . Indeed, before RDN all the patients had systolic blood pressure ≥160 mmHg, with a higher percentage .180 mmHg. At the 180th day after ablation all the patients had a systolic blood pressure ,180 mmHg, most ,140 mmHg.
Changes in antihypertensive medications after the procedure
The average number of antihypertensive drugs used per patient when evaluated at the 180th day after ablation (3.2 + 1.0) was reduced compared with baseline (4.7 + 1.3) (P , 0.0001) (Figure 4) . No patient demanded increase in the number of medications. In twentytwo patients, there was reduction in the number or dosage of medications. The classes of drugs and their respective dosages, expressed as median (range), at baseline and 6 month after the procedure are shown in Table 2 .
Renal function
There was a significant reduction in serum creatinine from 1.41 + 0.97 mg/dL at baseline to 1.16 + 0.94 mg/dL (P ¼ 0.0004), 1.19 + 1.00 mg/dL (P ¼ 0.0019), and 1.12 + 0.89 mg/dL (P , 0.0001) at 30, 90, and 180th days, respectively ( Table 3) To examine the influence of drug withdrawal on glomerular filtration, we compared the changes in such parameter according to the class of the discontinued drug. The mean changes in eGFR 180 days after the procedure in patients who had renin-angiotensin system inhibitors discontinued did not differ from the ones who were maintained on this family of BP drugs (21.5 + 14. 
Safety
From the 24 patients who underwent transcatheter RDN only one patient had bleeding requiring intervention at the puncture site of the femoral artery after the end of the procedure. The complication was adequately managed by mechanical compression, fluid infusion, and blood transfusion.
Real-time renal artery imaging was performed to assess eventual structural changes related to the procedure. Some small focal irregularities of the renal arteries that were present during the procedure (possibly due to minor spasm or oedema) were no longer seen postoperatively. At Days 30 and 180 after ablation all the patients underwent a new Doppler scan of renal arteries without any evidence of stenosis or flow limitation.
Discussion
In this clinical pilot study, we described a new approach to treat refractory hypertension in a population suffering from CKD using a SICAC.
In agreement with other studies in which SICAC was used 7,9 -12 and despite an arguably small number of patients, the intervention did not foster persistent adverse effects. At the end of this period, we have not observed any case of aneurysm or renal artery stenosis by echo Doppler. Renal sympathetic denervation led to marked reduction in systolic and diastolic blood pressure in patients with refractory hypertension and CKD. Office BP reduction was evident from the first 7 days post-procedure, and was sustained until the end of the short follow-up period of 180 days. It should be stressed that the magnitude of the mean systolic blood pressure reduction at the end of the observation period was 50 mmHg, a number higher than the one reported in previous studies. 4 -8 In addition, contrasting to a recent report, 25 values of the mean ABPM post-procedure in the present study were also significantly reduced. The decrease comprised both the awake and the sleeping periods. The number of dippers pre-and post-procedure was similar and so did the mean magnitude of BP reduction during the sleep. This is not unexpected considering that one major determinant of BP dipping is the circadian cycle of sympathetic activity 26 which may be influenced by RDN. We wonder if the differences in the catheter features may have contributed for these differences. The extension of lesions placement, as well the number of lesions per artery, has been suggested to matter for the obtained result. 27 A moderate correlation between the number of RF applications and the magnitude of the mean systolic blood pressure reduction at the 180th day after the procedure was found but our study was not designed to specifically address this issue. The chosen catheter is irrigated and has a gold-tipped electrode with a length almost four-fold higher than the catheter traditionally used in this type of procedure. 5, 6 The employment of an irrigation system 28 and the more extensive contact of the electrode with the vessel wall can conceivably allow more extensive and deeper lesion deployment, because the sympathetic nerves are largely located in the adventitia layer, 1.5-2 mm from the lumen of the renal artery. sympathetic outflow, which can be a major contributor to hypertension in this setting. 30 Indeed, a number of studies indicate that in the early stages of kidney disease, sympathetic activation is detectable, being directly proportional to the severity of renal failure. 31 -34 It should be mentioned that RDN is also known to be associated with increased natriuresis. 35 However, the extent of influence of this phenomenon on the BP reduction could not be dimensioned in our study because we did not address salt balance in our patients. How long-lived is the BP reduction is still unknown given the potential for sympathetic nerves to recover after lesion.
36 Consistent with previous reports, in which sustained effects have been reported for as long as 24 months, 5 patients showed no lessening of the achieved reduction in BP in the present study. Data suggest that there was neither recovery of nervous fibres nor development of effective counter-regulatory mechanisms capable of elevating the BP. The increase in the eGFR found that 180 days post-procedure in the present study is a unique finding. Our data apparently contrast with a recent study on CKD patients in which the eGFR 180 days post-procedure did not change. 25 However, the studied samples differ substantially. The majority of our patients belonged to CKD stage 2 (eGFR ≥60 mL/min/1.73 m 2 ) in contrast to patients from the prior study whose eGFR was ,45 mL/min/1.73 m 2 . When changes in eGFR in our study are analysed taking the baseline eGFR in consideration, it became clear that eGFR remained unchanged in patients ,45 mL/min/1.73 m 2 in agreement to that previous observation. The finding is not unexpected considering that structural changes are conceivably more consolidated in patients with advanced stages of CKD.
The relatively early change in the eGFR allowed us to resort to haemodynamic alterations as a plausible explanation for the phenomenon. Given the better control of BP, the withdrawal of antihypertensive drugs, especially the ones that impair the renin -angiotensin system (RAS) and diuretics, should be considered to explain the eGFR changes. This specific point was carefully addressed and the results obtained did not support this hypothesis. In addition, patients who had increases in eGFR were the ones who had reduction in the albumin excretion indicating that a harmful increase in glomerular pressure secondary to withdrawal of inhibitors of the RAS did not take place. In our view, a reasonable explanation would be that reduced sympathetic tonus may have led to decreased renal vascular resistance and increased renal blood flow which is known to be one of the major determinants of the glomerular filtration rate. 37 In conclusion, our results show that the use of SICAC at a wide range of applications of RF to produce renal sympathetic denervation in patients with refractory hypertension and CKD seem to be feasible, effective and, as far as our study is concerned, safe. It provides a highly significant reduction in BP and allows substantial reduction in the number of antihypertensive drugs used. Moreover, it was associated with increased eGFR and reduced albumin excretion in this short period of follow-up. Although encouraging, our data are preliminary and need to be validated in the long term.
Study limitations
The relatively small sample of the study can be seen as a limitation. However, as far as we could know, the present series is the largest one in the literature addressing percutaneous renal artery denervation in CKD patients. However, given the nature of the study, which is uncontrolled, our findings should be interpreted with caution.
The use of echo Doppler to assess damage in the renal arteries is in some way a limitation. However, early complications caused by the RF applications were excluded by angiography performed at the end of the procedure. Any other method, such as CT angiography, magnetic resonance angiography, or a new angiography of the renal arteries, could expose patients to additional undesirable toxic insults. Angiography using CO 2 is not available in our service. In addition, more precise methods of the assessment of GFR, such as cystatin C or iothalamate, should be used in future studies to confirm our finding regarding the effects of RDN upon the eGFR specially taking in consideration that only one measurement of serum creatinine was performed at each time point of the study.
